Skip to main content
SpringerLink
Log in

Significance of Plasma Osteopontin Levels in Patients with Bladder Urothelial Carcinomas

  • Original Research Article
  • Published:
Molecular Diagnosis & Therapy Aims and scope Submit manuscript

Abstract

Background and Objective

Previous studies have suggested that the plasma level of osteopontin may be a biomarker for cancer metastases and clinical prognosis; however, its role in bladder urothelial carcinoma (BUC) remains unknown. The purpose of this study was to explore the significance of plasma osteopontin levels in evaluating the pathologic features of BUC and its potential as a prognostic marker in BUC patients.

Methods

A total of 225 patients with BUC were enrolled in this study, and 230 age-matched and sex-matched healthy volunteers were enrolled as control subjects. The histologic classification of BUC, clinical stage of the disease, and plasma osteopontin levels were determined at admission. Patients with non-muscle-invasive BUC underwent transurethral resection, while those with muscle-invasive BUC underwent radical cystectomy. Patients receiving transurethral resection and radical cystectomy were followed up to determine their tumor-free interval and overall survival, respectively.

Results

The mean plasma osteopontin levels were significantly higher in BUC patients than in controls, significantly higher in patients with high-grade BUC than in those with low-grade BUC, and significantly higher in patients with muscle-invasive BUC than in those with non-muscle-invasive BUC. Patients with bladder-confined disease had the lowest osteopontin levels, while those with lymph node-positive disease had higher osteopontin levels, and those with metastatic BUC had the highest osteopontin expression. Kaplan–Meier analyses showed that a higher plasma osteopontin level was associated with a lower overall survival rate in muscle-invasive BUC patients receiving radical cystectomy.

Conclusion

Our results show that the plasma osteopontin level is associated with the clinical features of BUC and predicts the prognosis of muscle-invasive BUC in patients receiving radical cystectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Meran JG, Kudlacek S, Beke D. Systemic oncological treatment of bladder cancer. Wien Med Wochenschr. 2007;157:157–61.

    Article  PubMed  Google Scholar 

  2. Brunner A, Mayerl C, Tzankov A, et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol. 2004;57:927–31.

    Article  PubMed  CAS  Google Scholar 

  3. Thalmann GN. Prognostic markers for bladder cancer—are we there yet? Eur Urol. 2007;51:591–2.

    Article  PubMed  Google Scholar 

  4. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10:184–90.

    Article  PubMed  CAS  Google Scholar 

  5. Xie H, Song J, Du R, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis. 2007;39:167–72.

    Article  PubMed  CAS  Google Scholar 

  6. Zhao L, Li T, Wang Y, et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract. 2008;62:1056–62.

    Article  PubMed  CAS  Google Scholar 

  7. Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782–9.

    Article  PubMed  CAS  Google Scholar 

  8. Patani N, Jouhra F, Jiang W, et al. Osteopontin expression profiles predict pathological and clinical outcome in breast cancer. Anticancer Res. 2008;28:4105–10.

    PubMed  CAS  Google Scholar 

  9. Chang YS, Kim HJ, Chang J, et al. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer. 2007;57:373–80.

    Article  PubMed  Google Scholar 

  10. Musial K, Fornalczyk K, Zwolinska D. Osteopontin (OPN), PDGF-BB (platelet-derived growth factor) and BMP-7 (bone morphogenetic protein) as markers of atherogenesis in children with chronic kidney disease (CKD) treated conservatively—preliminary results. Pol Merkur Lekarski. 2008;24(Suppl. 4):25–7.

    PubMed  Google Scholar 

  11. Cho H, Hong SW, Oh YJ, et al. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol. 2008;134:909–17.

    Article  PubMed  CAS  Google Scholar 

  12. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22:1435–48.

    Article  PubMed  CAS  Google Scholar 

  13. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition, Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;1997(80):1803–4.

    Article  Google Scholar 

  14. Fong YC, Liu SC, Huang CY, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer. 2009;64:263–70.

    Article  PubMed  Google Scholar 

  15. Devoll RE, Pinero GJ, Appelbaum ER, et al. Improved immunohistochemical staining of osteopontin (OPN) in paraffin-embedded archival bone specimens following antigen retrieval: anti-human OPN antibody recognizes multiple molecular forms. Calcif Tissue Int. 1997;60:380–6.

    Article  PubMed  CAS  Google Scholar 

  16. El-Tanani MK, Campbell FC, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006;17:463–74.

    Article  PubMed  CAS  Google Scholar 

  17. Kolb A, Kleeff J, Guweidhi A, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther. 2005;4:740–6.

    Article  PubMed  CAS  Google Scholar 

  18. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med. 1999;160:1269–73.

    Article  PubMed  CAS  Google Scholar 

  19. Cui BK, Zhang CQ, Zhang Y, et al. Osteopontin as a potential biomarker of metastasis and recurrence for hepatocellular carcinoma. Ai Zheng. 2006;25:876–9.

    PubMed  CAS  Google Scholar 

  20. Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709–17.

    Article  PubMed  CAS  Google Scholar 

  21. Yang GH, Fan J, Xu Y, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist. 2008;13:1155–65.

    Article  PubMed  CAS  Google Scholar 

  22. Hotte SJ, Winquist EW, Stitt L, et al. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer. 2002;95:506–12.

    Article  PubMed  CAS  Google Scholar 

  23. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer. 2000;83:156–63.

    Article  PubMed  CAS  Google Scholar 

  24. Cook AC, Chambers AF, Turley EA, et al. Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem. 2006;281:24381–9.

    Article  PubMed  CAS  Google Scholar 

  25. Takahashi F, Takahashi K, Okazaki T, et al. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2001;24:264–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Li Zhao and Yalin Wang contributed equally to this work and should be considered joint first authors of the article. The authors thank Dr. Min Huang for his help with the statistical analysis. No sources of funding were used to conduct this study or prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Department of Urology, Affiliated Hospital of Academy of Military Medical Sciences, No. 8, East Street, Fengtai District, 100000, Beijing, China

    Li Zhao, Yalin Wang, Nan Qu, Chen Huang & Lijun Chen

Authors
  1. Li Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yalin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nan Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chen Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lijun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lijun Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, L., Wang, Y., Qu, N. et al. Significance of Plasma Osteopontin Levels in Patients with Bladder Urothelial Carcinomas. Mol Diagn Ther 16, 311–316 (2012). https://doi.org/10.1007/s40291-012-0005-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40291-012-0005-4

Keywords

Search

Navigation